每日一次的多替格拉韦/拉米夫定固定剂量制剂在艾滋病毒感染儿童中的应用:一项开放标签、多中心、随机、非劣效性D3/PENTA 21试验的药代动力学和安全性亚研究

IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Lisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, Elizabeth Kaudha, Grace M Ahimbisibwe, Isabelle Deprez, Tiyara Arumugan, Ebrahim Variava, Avy Violari, Iona White, Dickson Bbuye, Annet Nanduudu, Enoch Mulwanyi, Pauline Amuge, Diana A Rutebarika, Adeodata Kekitiinwa, Cissy Kityo, Philippa Musoke, Moherndran Archary, Justine Boles, Margaret J Thomason, Saskia N de Wildt, Carlo Giaquinto, Angela Colbers, David M Burger, Ann M Buchanan, Man K Chan, Tom G Jacobs, Anna Turkova
{"title":"每日一次的多替格拉韦/拉米夫定固定剂量制剂在艾滋病毒感染儿童中的应用:一项开放标签、多中心、随机、非劣效性D3/PENTA 21试验的药代动力学和安全性亚研究","authors":"Lisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, Elizabeth Kaudha, Grace M Ahimbisibwe, Isabelle Deprez, Tiyara Arumugan, Ebrahim Variava, Avy Violari, Iona White, Dickson Bbuye, Annet Nanduudu, Enoch Mulwanyi, Pauline Amuge, Diana A Rutebarika, Adeodata Kekitiinwa, Cissy Kityo, Philippa Musoke, Moherndran Archary, Justine Boles, Margaret J Thomason, Saskia N de Wildt, Carlo Giaquinto, Angela Colbers, David M Burger, Ann M Buchanan, Man K Chan, Tom G Jacobs, Anna Turkova","doi":"10.1016/j.ebiom.2025.105929","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Two-drug regimen dolutegravir/lamivudine (DTG/3TC) is recommended as an alternative to standard three-drug regimens in adult treatment guidelines. This nested pharmacokinetic sub-study within the D3/Penta 21 randomised trial (#NCT04337450) assessed DTG and 3TC concentrations and safety in virologically-suppressed children, switching to once-daily DTG/3TC fixed-dose formulations.</p><p><strong>Methods: </strong>Children aged 2-<15 years received either 5/30 mg DTG/3TC dispersible tablets (DT) or 50/300 mg film-coated tablets (FCT), using WHO weight band (WB)-aligned dosing: 10-<14 kg 4 DTs; 14-<20 kg 5 DTs; 20-<25 kg 6 DTs or 1 FCT; 25-<40 kg 1 FCT. A minimum of 8-evaluable pharmacokinetic curves per WB/formulation were targeted for 24 h pharmacokinetic profiling (t = 0, 1, 2, 3, 4, 6, and 24 h post-dosing) at steady state. The number of children with DTG C<sub>trough</sub> <0.32 mg/L (EC90) and <0.064 mg/L (PA-IC90) were summarised. Safety was evaluated through 48 weeks in eligible children consented to the pharmacokinetic sub-study.</p><p><strong>Findings: </strong>Between 11th May 2022 and 31st May 2023, 82 children consented for the sub-study. Seventy-two were included in the pharmacokinetic analysis; median (IQR) age was 7.1 (4.9-10.0) years and weight 21.6 (17.7-24.8) kg. DTG geometric mean (GM) (%CV) C<sub>trough</sub> and AUC<sub>0-24 h</sub> were 0.82 (54) mg/L and 66.2 (35) h∗mg/L. 3TC GM-AUC<sub>0-24 h</sub> was 16.2 (45) h∗mg/L. Three children had DTG C<sub>trough</sub><0.32 mg/L, all had DTG C<sub>trough</sub> ≥0.064 mg/L. In children weighing 20-<25 kg WB and taking 1 FCT (50/300 mg) 3TC GM AUC<sub>0-24 h</sub> was 19% higher than in children ≥25 kg (1 FCT). Of 82 children, 3 had 4 serious adverse events (SAEs) and 5 had 6 grade ≥3 adverse events (AEs). No AEs were related to DTG/3TC or resulted in treatment discontinuation. No 3TC-related AEs or laboratory abnormalities were observed in children taking FCT in the 20-<25 kg WB. PK parameters were comparable to historical paediatric data from ODYSSEY (DTG) and IMPAACT2019 (3TC) trials.</p><p><strong>Interpretation: </strong>The study demonstrated adequate DTG and 3TC exposures with reassuring safety profiles using WB-based dosing, supporting licencing applications for dispersible and film-coated DTG/3TC formulations for paediatric use.</p><p><strong>Funding: </strong>The D3/Penta 21 trial is sponsored by Fondazione Penta Onlus ETS (Penta) and funded by ViiV Healthcare.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"120 ","pages":"105929"},"PeriodicalIF":10.8000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.\",\"authors\":\"Lisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, Elizabeth Kaudha, Grace M Ahimbisibwe, Isabelle Deprez, Tiyara Arumugan, Ebrahim Variava, Avy Violari, Iona White, Dickson Bbuye, Annet Nanduudu, Enoch Mulwanyi, Pauline Amuge, Diana A Rutebarika, Adeodata Kekitiinwa, Cissy Kityo, Philippa Musoke, Moherndran Archary, Justine Boles, Margaret J Thomason, Saskia N de Wildt, Carlo Giaquinto, Angela Colbers, David M Burger, Ann M Buchanan, Man K Chan, Tom G Jacobs, Anna Turkova\",\"doi\":\"10.1016/j.ebiom.2025.105929\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Two-drug regimen dolutegravir/lamivudine (DTG/3TC) is recommended as an alternative to standard three-drug regimens in adult treatment guidelines. This nested pharmacokinetic sub-study within the D3/Penta 21 randomised trial (#NCT04337450) assessed DTG and 3TC concentrations and safety in virologically-suppressed children, switching to once-daily DTG/3TC fixed-dose formulations.</p><p><strong>Methods: </strong>Children aged 2-<15 years received either 5/30 mg DTG/3TC dispersible tablets (DT) or 50/300 mg film-coated tablets (FCT), using WHO weight band (WB)-aligned dosing: 10-<14 kg 4 DTs; 14-<20 kg 5 DTs; 20-<25 kg 6 DTs or 1 FCT; 25-<40 kg 1 FCT. A minimum of 8-evaluable pharmacokinetic curves per WB/formulation were targeted for 24 h pharmacokinetic profiling (t = 0, 1, 2, 3, 4, 6, and 24 h post-dosing) at steady state. The number of children with DTG C<sub>trough</sub> <0.32 mg/L (EC90) and <0.064 mg/L (PA-IC90) were summarised. Safety was evaluated through 48 weeks in eligible children consented to the pharmacokinetic sub-study.</p><p><strong>Findings: </strong>Between 11th May 2022 and 31st May 2023, 82 children consented for the sub-study. Seventy-two were included in the pharmacokinetic analysis; median (IQR) age was 7.1 (4.9-10.0) years and weight 21.6 (17.7-24.8) kg. DTG geometric mean (GM) (%CV) C<sub>trough</sub> and AUC<sub>0-24 h</sub> were 0.82 (54) mg/L and 66.2 (35) h∗mg/L. 3TC GM-AUC<sub>0-24 h</sub> was 16.2 (45) h∗mg/L. Three children had DTG C<sub>trough</sub><0.32 mg/L, all had DTG C<sub>trough</sub> ≥0.064 mg/L. In children weighing 20-<25 kg WB and taking 1 FCT (50/300 mg) 3TC GM AUC<sub>0-24 h</sub> was 19% higher than in children ≥25 kg (1 FCT). Of 82 children, 3 had 4 serious adverse events (SAEs) and 5 had 6 grade ≥3 adverse events (AEs). No AEs were related to DTG/3TC or resulted in treatment discontinuation. No 3TC-related AEs or laboratory abnormalities were observed in children taking FCT in the 20-<25 kg WB. PK parameters were comparable to historical paediatric data from ODYSSEY (DTG) and IMPAACT2019 (3TC) trials.</p><p><strong>Interpretation: </strong>The study demonstrated adequate DTG and 3TC exposures with reassuring safety profiles using WB-based dosing, supporting licencing applications for dispersible and film-coated DTG/3TC formulations for paediatric use.</p><p><strong>Funding: </strong>The D3/Penta 21 trial is sponsored by Fondazione Penta Onlus ETS (Penta) and funded by ViiV Healthcare.</p>\",\"PeriodicalId\":11494,\"journal\":{\"name\":\"EBioMedicine\",\"volume\":\"120 \",\"pages\":\"105929\"},\"PeriodicalIF\":10.8000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EBioMedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ebiom.2025.105929\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2025.105929","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:在成人治疗指南中,推荐双药方案多替格拉韦/拉米夫定(DTG/3TC)作为标准三药方案的替代方案。D3/Penta 21随机试验(#NCT04337450)中的巢式药代动力学亚研究评估了DTG和3TC在病毒学抑制儿童中的浓度和安全性,转而使用每日一次的DTG/3TC固定剂量制剂。研究结果:在2022年5月11日至2023年5月31日期间,82名儿童同意参加该子研究。72例纳入药代动力学分析;中位(IQR)年龄为7.1(4.9-10.0)岁,体重为21.6 (17.7-24.8)kg, DTG几何平均(GM) (%CV)通过和AUC0-24 h分别为0.82 (54)mg/L和66.2 (35)h∗mg/L。3TC GM-AUC0-24 h为16.2 (45)h∗mg/L。3例患儿DTG≥0.064 mg/L。体重20-0-24 h的儿童比体重≥25 kg的儿童高19% (1 FCT)。82例患儿中,3例发生4次严重不良事件(sae), 5例发生6次≥3级不良事件(ae)。没有与DTG/3TC相关的ae或导致治疗中断。解释:该研究表明,使用基于wb的剂量,DTG和3TC暴露量充足,安全性令人放心,支持用于儿科使用的分散性和覆膜DTG/3TC配方的许可申请。资金:D3/Penta 21试验由基金会Penta onplus ETS (Penta)赞助,ViiV Healthcare资助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Background: Two-drug regimen dolutegravir/lamivudine (DTG/3TC) is recommended as an alternative to standard three-drug regimens in adult treatment guidelines. This nested pharmacokinetic sub-study within the D3/Penta 21 randomised trial (#NCT04337450) assessed DTG and 3TC concentrations and safety in virologically-suppressed children, switching to once-daily DTG/3TC fixed-dose formulations.

Methods: Children aged 2-<15 years received either 5/30 mg DTG/3TC dispersible tablets (DT) or 50/300 mg film-coated tablets (FCT), using WHO weight band (WB)-aligned dosing: 10-<14 kg 4 DTs; 14-<20 kg 5 DTs; 20-<25 kg 6 DTs or 1 FCT; 25-<40 kg 1 FCT. A minimum of 8-evaluable pharmacokinetic curves per WB/formulation were targeted for 24 h pharmacokinetic profiling (t = 0, 1, 2, 3, 4, 6, and 24 h post-dosing) at steady state. The number of children with DTG Ctrough <0.32 mg/L (EC90) and <0.064 mg/L (PA-IC90) were summarised. Safety was evaluated through 48 weeks in eligible children consented to the pharmacokinetic sub-study.

Findings: Between 11th May 2022 and 31st May 2023, 82 children consented for the sub-study. Seventy-two were included in the pharmacokinetic analysis; median (IQR) age was 7.1 (4.9-10.0) years and weight 21.6 (17.7-24.8) kg. DTG geometric mean (GM) (%CV) Ctrough and AUC0-24 h were 0.82 (54) mg/L and 66.2 (35) h∗mg/L. 3TC GM-AUC0-24 h was 16.2 (45) h∗mg/L. Three children had DTG Ctrough<0.32 mg/L, all had DTG Ctrough ≥0.064 mg/L. In children weighing 20-<25 kg WB and taking 1 FCT (50/300 mg) 3TC GM AUC0-24 h was 19% higher than in children ≥25 kg (1 FCT). Of 82 children, 3 had 4 serious adverse events (SAEs) and 5 had 6 grade ≥3 adverse events (AEs). No AEs were related to DTG/3TC or resulted in treatment discontinuation. No 3TC-related AEs or laboratory abnormalities were observed in children taking FCT in the 20-<25 kg WB. PK parameters were comparable to historical paediatric data from ODYSSEY (DTG) and IMPAACT2019 (3TC) trials.

Interpretation: The study demonstrated adequate DTG and 3TC exposures with reassuring safety profiles using WB-based dosing, supporting licencing applications for dispersible and film-coated DTG/3TC formulations for paediatric use.

Funding: The D3/Penta 21 trial is sponsored by Fondazione Penta Onlus ETS (Penta) and funded by ViiV Healthcare.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
EBioMedicine
EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
17.70
自引率
0.90%
发文量
579
审稿时长
5 weeks
期刊介绍: eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信